Product Description
Mechanisms of Action: Imaging Agent
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: Topical
FDA Designation: Fast Track - *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Photocure
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Bladder Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PC B309/21 / YHCT-HEX-B1 | P3 |
Completed |
Bladder Cancer |
2023-07-12 |
|
| CTR20221172 | P3 |
Active, not recruiting |
Bladder Cancer |
None |